Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis
Shuang Li(Harbin Medical University), Lihua Wang(Jiangxi University of Traditional Chinese Medicine), Chunrui Bo(Harbin Medical University), Yuze Cao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaotong Kong(Howard Hughes Medical Institute), Yang Jiao(Harbin Medical University), Xiaoyu Lu(Harbin Medical University), Zhaojun Liu(ZheJiang Academy of Agricultural Sciences), Lei Li(Xuzhou Medical College), Lixia Chen(Shanxi University of Traditional Chinese Medicine), Jianjian Wang(University Town of Shenzhen), Shangwei Ning(Harbin Medical University), Peifang Liu(Fujian Medical University), Huixue Zhang(Harbin Medical University)
Cited by 9
Related Papers
Regulation of <i>Notch1</i> and <i>Dll4</i> by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis
|Molecular and Cellular Biology|2002|502
Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers
|Nucleic Acids Research|2015|386
The mRNA related ceRNA–ceRNA landscape and significance across 20 major cancer types
|Nucleic Acids Research|2015|209
Modulating influence on HIV/AIDS by interacting <i>RANTES</i> gene variants
|Proceedings of the National Academy of Sciences|2002|189
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
|Journal of Medicinal Chemistry|2021|186